ACCP Cardiology PRN Journal Club

Slides:



Advertisements
Similar presentations
The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
Advertisements

A Comparison of Angiotensin Receptor-Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced.
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.
Jim Hoehns, Pharm.D.. ClassificationEF (%)Description HF with reduced EF (HFrEF) ≤40 “systolic HF”; RCTs have mainly enrolled these HF patients; only.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
חזק בהגנה לבבית Valsartan in Heart Failure
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACCP Cardiology PRN Journal Club
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
ACCP Cardiology PRN Journal Club
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie,
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Entresto® (sacubitril & valsartan)
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
PARADIGM-HF A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
ACCP Cardiology PRN Journal Club
PARADIGM-HF Study Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure A multicenter, randomized,
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
ACCP Cardiology PRN Journal Club
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Natural History of Heart Failure
OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.
Interim Chair, Medicine Brigham and Women’s Hospital Boston, MA
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Eric J Robinson, M.D. Cardiologist April 25, 2015
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Disclosure Statement Philip Leong Potential conflicts of interest: none Sponsorship: none Speaker’s presentation is educational in nature and indicates.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
CLINICAL DILEMMAS IN HEART FAILURE:
EMPHASIS-HF Extended Follow-up
Diabetes Mellitus and Heart Failure
Clyde W. Yancy et al. JACC 2017;70:
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Presentation transcript:

ACCP Cardiology PRN Journal Club

Announcements Thank you attending the ACCP Cardiology PRN Journal Club Thank you if you attended last time I have created a PB Works Site that will house our recorded calls, handouts, and Summary/Q&A documents. I will be e- mailing the link to this in the next 1-2 weeks. Still trying to explore option of getting CE. If there are any suggestions, please let us know.

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) Prepared By: Robert K. Tunney, PharmD, BCPS PGY2 Cardiology Resident, Vanderbilt University Medical Center, Nashville, TN McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Disclosures I have no financial interest or affiliation with the manufacturer of any marketed product discussed herein

Background Heart Failure (HF) Constellation of symptoms 5.1 million Americans (and rising) with HF ~20% lifetime risk for the development of HF in patients > 40 years old Lack of consistency in mortality benefit with angiotensin- receptor blockers (ARBs) CHARM (2004) and Val-HeFT (2001) 2013 ACC/AHA Guidelines: ARBs recommended in patients intolerant to ACE-I therapy (IA) McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004. Yancy CW, et al. JACC. 2013; 62(16): e147-e239.

Background: Neprilysin Inhibition (NI) LCZ696 Inactive Metabolite AHU377 (sacubitril) Natriuretic peptide system Renin-angiotensin system Natriuretic Peptides Angiotensinogen (liver) Angiotensin I Inactive Fragments Valsartan Angiotensin II 1.) Vasodilation 2.) Natriuresis/diuresis 1.) Vasoconstriction Adapted from Bonow RO, et al. Global Cardiology Science and Practice. 2014; 34: dx.doi.org/10.5339/gcsp.2014.34. Fig. 1.

Background and Purpose OCTAVE trial (2004): Neprilysin (omapatrilat) and ACE-I combination  intolerance secondary to angioedema LCZ696: sacubitril + valsartan (fixed molecular complex) Purpose Assess the relative superiority of morbidity and mortality benefits between LCZ696 200 mg BID and ACE inhibition (enalapril 10 mg BID) in patients with HFrEF McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Study Design Randomized, double-blind, parallel group, active-control trial of 8,442 patients in 47 different countries Screening Period (Visit 1) Single-blind run-in Period 5-10 weeks (Visits 2-4) Double-blind, randomized treatment period: 22 months (Visit 5) McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Study Design: Run-In Period McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Study Demographics Characteristic LCZ696 (n = 4187) Enalapril (n = 4212) Region North America 310 (7.4%) 292 (6.9%) NYHA Functional Class I 180 (4.3%) 209 (5.0%) II 2998 (71.6%) 2921 (69.3%) III 969 (23.1%) 1049 (24.9%) IV 33 (0.8%) 27 (0.6%) Medical History Implantable cardioverter-defibrillator 623 (14.9%) 620 (14.7%) Cardiac resynchronization therapy (CRT) 292 (7.0%) 282 (6.7%) McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Methods Inclusion Criteria Exclusion Criteria CHF (NYHA Class II-IV) Hypotension (SBP < 100 mmHg at screening or < 95 mmHg at randomization) Male or female aged >18 yrs Known history of angioedema LVEF < 40% (within the past six months prior to randomization) – changed to < 35% in 12/10 Patients in acute decompensated HF BNP > 150 pg/mL or NT-proBNP > 600 pg/mL at visit 1 Estimated eGFR < 30 mL/min/1.73 m2 (MDRD) Stable dose of an ACE-I or ARB for 4 weeks prior to visit 1 Serum potassium > 5.2 mmol/L (visit 1) or > 5.4 mmol/L at visit 3 or 5 Stable dose of beta-blocker for 4 weeks prior to visit 1 (unless contraindicated) CVA, ACS, ventricular arrhythmia, or cardiac resynchronization device within the previous 3 months McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Outcomes Primary: Secondary: Time to first occurrence of composite endpoint: CV death or HF hospitalization Improvement in the Kansas City Cardiomyopathy Questionaire (KCCQ) at 8 months All-cause mortality Decline in renal function defined as: 1.) 50% eGFR reduction (relative to baseline 2.) > 30% reduction in eGFR (relative to baseline) 3.) Progression to ESRD Decline in renal function New-onset atrial fibrillation McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Statistics Primary efficacy variable  Cox proportional hazards model (alpha = 0.05, two tail) Kaplan-Meier curves to summarize primary composite endpoint Sample Size  7,980 patients 34 months 1,229 CV-related deaths Assumed 7% annual CV death rate Est rate of primary end point = 14.5% (CHARM-Added Trial) Three planned interim efficacy analyses (33%, 50%, and 67% event accrual) 80% power to detect a relative reduction of 15% in CV-related deaths within the treatment group McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Primary composite endpoint (%) Secondary Outcomes (%) Results Study Outcome LCZ696 (n = 4187) Enalapril (n = 4212) Hazard Ratio (HR) P-Value Primary composite endpoint (%) 1.) Death from CV causes 558 (13.3) 693 (16.5) 0.80 (0.71-0.89) <0.001 2.) 1st hosp. for worsening HF 537 (12.8) 658 (15.6) 0.79 (0.71-0.89) Secondary Outcomes (%) 1.) Death from any cause 711 (17.0) 835 (19.8) 0.84 (0.76-0.93) 2.) KCCQ Score change (8 months) -2.99 +0.36 -4.63 +0.36 1.64 (0.63-2.65) 0.001 3.) Decline in renal function 94 (2.2) 108 (2.6) 0.86 (0.65-1.13) 0.28 4.) New Afib 84 (3.1) 83 (3.1) 0.97 (0.72-1.31) 0.83 McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Results Adverse Events LCZ696 (n = 4187) Enalapril (n = 4212) P-Value Hypotension 1.) Symptomatic 588 (14%) 388 (9.2) < 0.001 2.) Symptomatic (SBP < 90 mmHg) 112 (2.7%) 59 (1.4%) Elevated SCr 1.) > 2.5 mg/dL 139 (3.3%) 188 (4.5%) 0.007 2.) > 3.0 mg/dL 63 (1.5%) 83 (2.0%) 0.10 Cough 474 (11.3%) 601 (14.3%) Angioedema 1.) No treatment/antihistamine only 10 (0.2%) 5 (0.1%) 0.19 2.) Hospitalization (no airway compromise) 3 (0.1%) 1 (<0.1%) 0.31 McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Results McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Discussion Inhibition of both angiotensin II receptors and neprilysin was more effective in reducing morbidity and mortality relative to the control therapy Mean enalapril dose utilized = 18.9 mg daily CONSENSUS (1987): 18.4 mg – 20 mg BID target dose SOLVD (1991): 16.6 mg – 10 mg BID target dose LCZ696 resulted in greater incidence of hypotension but was not associated with significant increases in serious angioedema McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Author’s Conclusion Angiotensin-receptor-neprilysin inhibition with LCZ696 proves superior to ACE inhibition alone in reducing the risk of death and re-hospitalization due to HF McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Critique Strengths Weaknesses Thought-Provoking Study Design Robust statistical power High statistical significance Potential degree of clinical significance Weaknesses Were the “sickest” patients studied? Reproducibility to U.S. patients Under-representation of ICD/CRT patients and those of African descent Thought-Provoking Reduction in atrial fibrillation Comparative efficacy of valsartan 320 mg versus enalapril 20 mg Previous use of ACE/ARB Drug run-in period Cost-prohibitive therapy McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004. Yancy, Clyde W. "Commentary on PARADIGM HF Study Design." ESC 2014 Science News (31 Aug. 2014).

Impact on Clinical Practice Potential exists for a profound impact on HF pharmacotherapy Considerations for utilization in specific patients: Patients with past history of angioedema are excluded Lack of reproducible safety data in patients of African descent (OCTAVE) Insurance status Previous use and tolerance of an ACE-I/ARB McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004. Kostis JB, et al. Am J Hypertens. 2004; 17: 103-111.

Acknowledgements Journal Club Mentors Program Director 1.) Elizabeth McNeely, PharmD, BCPS TriStar Centennial Medical Center, Nashville, TN 2.) Herb Patterson, PharmD, FCCP UNC Eshelman School of Pharmacy, Chapel Hill, NC Program Director Daniel Johnson, PharmD, BCPS(AQ-Cardiology) Vanderbilt University Medical Center, Nashville, TN ACC PRN Journal Club Coordinator Craig Beavers; PharmD, BCPS (AQ-Cardiology)

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) Prepared By: Robert K. Tunney, PharmD, BCPS PGY2 Cardiology Resident, Vanderbilt University Medical Center, Nashville, TN McMurray JV, et al. N Eng J Med. 2014; 371: 993-1004.

Thank you for attending! If you would like to have your resident present, would like to be a mentor, or have questions or comments please e- mail the journal club at accpcardsprnjournalclub@gmail.com or craig.beaverspharmd@gmail.com Our next Journal Club will be in early January with the date to be determined. Nicole Gasbarro from University of Chicago-Illinois will be presenting DAPT trial.